Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 901 in previously untreated unresectable or metastatic urothelial cancer
NL-OMON60358Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma (TCC) comparing Nivolumab + ipilimumab with Standard-of-care chemotherapy (2 arms). Primary endpoints: Overall survival in cisplatin-ineligible randomized participants and Overall survival in PD-L1-positive randomized participants. Started May 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON60358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60358.